Type 2 Diabetes Trial, Recruiting NCT06329544 Sponsor: Icahn School of Medicine at Mount Sinai Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06329544
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed to have fructose malabsorption (difficulty absorbing a type of sugar called fructose) through a hydrogen breath test done at the screening visit.

Who may not be able to join:

  • People who are currently taking probiotic, prebiotic, or synbiotic supplements
  • People who drink more than one sugary drink (such as soda or sweetened juice) per day
  • People who have taken antibiotics in the 3 months before joining, or who need to take antibiotics during the trial
  • People who follow a vegetarian, vegan, or other restrictive diet
  • People who have a food allergy
  • People who drink more than 2 alcoholic drinks per day
  • People who have been diagnosed by a doctor with a serious medical condition, including type 1 or type 2 diabetes, or an eating disorder
  • People who have a physical, mental, or cognitive condition that would prevent them from participating
  • People who regularly take any medication that may affect body weight, body composition, insulin resistance, or cholesterol/fat levels in the blood
  • People who currently smoke (more than one cigarette in the past week) or use recreational drugs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ryan Walker, Icahn School of Medicine at Mount Sinai

Phone: 212-824-7088

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 October 2024
Est. completion
31 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Liver proton density fat fraction (PDFF); Degree of fibrosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov